You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 14, 2025

CLINICAL TRIALS PROFILE FOR HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000468 ↗ Myocardial Infarction Triage and Intervention Project (MITI) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1988-04-01 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00000468 ↗ Myocardial Infarction Triage and Intervention Project (MITI) Completed University of Washington Phase 3 1988-04-01 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Australian and New Zealand Intensive Care Society Clinical Trials Group Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Canadian Critical Care Trials Group Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Canadian Institutes of Health Research (CIHR) Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container

Condition Name

Condition Name for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container
Intervention Trials
Covid19 4
Myocardial Infarction 4
Healthy 4
Thrombosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container
Intervention Trials
Thrombosis 13
Venous Thrombosis 7
Acute Kidney Injury 6
COVID-19 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container

Trials by Country

Trials by Country for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container
Location Trials
United States 44
China 16
Canada 14
Brazil 12
Germany 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container
Location Trials
California 7
New York 5
Texas 4
Ohio 3
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase Trials
Phase 4 27
Phase 3 15
Phase 2/Phase 3 6
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase Trials
Completed 47
Unknown status 13
Withdrawn 10
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container

Sponsor Name

Sponsor Name for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container
Sponsor Trials
Ain Shams University 5
GlaxoSmithKline 4
Azidus Brasil 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container
Sponsor Trials
Other 143
Industry 35
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container: Clinical Trials, Market Analysis, and Projections

Introduction

Heparin sodium, a widely used anticoagulant, has been a cornerstone in medical treatment for over 80 years, particularly for preventing blood clots and treating conditions such as heart attacks and strokes. This article delves into the current clinical trials, market analysis, and future projections for heparin sodium, specifically the formulation of 2,000 Units in Sodium Chloride 0.9% in plastic containers.

Clinical Trials Update

Intranasal Heparin Trial (INHERIT)

One of the most significant ongoing clinical trials involving heparin is the INHERIT trial. This trial, conducted by Murdoch Children's, The University of Melbourne, Monash University, and the Northern Hospital, aims to assess the efficacy and safety of intranasal heparin for the treatment of early COVID-19 infection and the prevention of its spread within household contacts. The trial also investigates the effect of heparin on "long COVID" symptoms that persist more than 12 weeks after the initial infection.

Heparin's potential in this context is based on its ability to bind to the COVID-19 virus, thereby reducing its ability to enter cells and multiply. This approach is crucial given the ongoing need for effective treatments beyond vaccination[1].

Intravenous Administration Studies

Another area of clinical research involves the intravenous administration of heparin sodium. A phase I study by União Química focuses on determining the pharmacodynamic profile of sodium heparin of porcine origin in healthy male participants. This study evaluates the toxicity and pharmacokinetic profile of the drug, adhering to the guidelines of the National Health Surveillance Agency (ANVISA)[4].

Market Analysis

Global Market Size and Forecast

The heparin sodium market has been growing steadily, driven by several factors. As of 2024, the global heparin sodium market was valued at USD 5.76 billion and is projected to reach USD 9.72 billion by 2031, growing at a CAGR of 4.2% during the forecast period[5].

Regional Analysis

The market is segmented geographically into North America, Europe, Asia Pacific, and the rest of the world. North America is expected to hold the largest market share, fueled by significant investments in research and development and the presence of major players. The increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer also contributes to the market growth in this region[5].

Emerging Markets and Applications

In emerging markets, the demand for heparin sodium tubes is rising due to the increasing need for blood collection and testing. The growing awareness about the importance of regular blood testing for early disease detection and prevention has boosted the demand for heparin sodium tubes. Additionally, their use in clinical research for drug development and evaluation is expected to further drive market growth[2].

Market Drivers

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as diabetes, cardiovascular diseases, and cancer has significantly increased the demand for heparin sodium. These conditions require frequent blood testing, which in turn increases the need for heparin sodium tubes for blood collection[2].

Growing Awareness of Regular Blood Testing

The importance of regular blood testing for early disease detection and prevention has become more widely recognized. This growing awareness has led to an increased demand for heparin sodium tubes, contributing to market growth[2].

Clinical Research and Drug Development

Heparin sodium tubes are increasingly used in clinical research for drug development and evaluation. This adoption is expected to drive the market further over the forecast period[2].

Product Characteristics and Safety

Heparin Sodium in Sodium Chloride Injection

Heparin sodium in 0.9% sodium chloride injection is a clear solution available in single-dose containers. It is crucial to note that the rate of clearance of unfractionated heparin may be decreased in patients with renal or hepatic impairment, leading to higher plasma levels of heparin in these patients compared to those with normal renal and hepatic function[3].

Stability and Availability

Heparin is safe, inexpensive, and stable for long periods at room temperature, making it a viable option for global use. Its widespread availability is a significant advantage, especially in the context of managing pandemics like COVID-19[1].

Future Projections

Market Growth

The heparin sodium market is expected to continue growing, driven by the increasing demand for anticoagulant treatments and the expanding use in clinical research. The projected CAGR of 4.2% from 2024 to 2031 indicates a robust market with significant potential for growth[5].

New Applications and Research

The ongoing research into new applications of heparin, such as its use in treating COVID-19, suggests that the drug may find new avenues for use beyond its traditional anticoagulant role. This could further boost market growth and expand the drug's utility in various medical contexts[1].

Key Takeaways

  • Clinical Trials: Ongoing trials like the INHERIT trial are exploring heparin's efficacy in treating COVID-19 and preventing its spread.
  • Market Growth: The global heparin sodium market is projected to grow from USD 5.76 billion in 2024 to USD 9.72 billion by 2031.
  • Regional Dominance: North America is expected to hold the largest market share due to significant investments in R&D and the presence of major players.
  • Market Drivers: Increasing prevalence of chronic diseases, growing awareness of regular blood testing, and use in clinical research are key drivers.
  • Product Characteristics: Heparin sodium is safe, inexpensive, and stable, with considerations for patients with renal or hepatic impairment.

FAQs

Q: What is the primary focus of the INHERIT trial involving heparin sodium?

A: The INHERIT trial focuses on assessing the efficacy and safety of intranasal heparin for treating early COVID-19 infection and preventing its spread within household contacts.

Q: How does the global heparin sodium market project to grow in the coming years?

A: The global heparin sodium market is projected to grow from USD 5.76 billion in 2024 to USD 9.72 billion by 2031, at a CAGR of 4.2%.

Q: What are the key drivers of the heparin sodium market growth?

A: The key drivers include the increasing prevalence of chronic diseases, growing awareness of regular blood testing, and the use of heparin sodium tubes in clinical research.

Q: What are the safety considerations for patients using heparin sodium in sodium chloride injection?

A: Patients with renal or hepatic impairment may have higher plasma levels of heparin due to decreased clearance rates.

Q: What is the significance of heparin's stability and availability?

A: Heparin's stability at room temperature and its widespread availability make it a viable option for global use, especially in managing pandemics.

Sources

  1. Intranasal Heparin Trial (INHERIT) - Murdoch Children's Research Institute.
  2. Heparin Sodium Tube in Emerging Markets: Analysis and ... - Data Insights Market.
  3. Heparin Sodium in 0.9% Sodium Chloride Injection - Pfizer Medical Information.
  4. Study With Heparin Sodium in Intravenous Administration - Veeva Systems.
  5. In-Depth Industry Outlook: Heparin Sodium Market Size, Forecast - Verified Market Research.
Last updated: 2025-01-06

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.